Connor, Clark & Lunn Investment Management Ltd. C4 Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$5.3 - $11.0 $32,531 - $67,518	6,138 Added 3.65%	174,356 $1.42 Million
Q4 2023 Feb 09, 2024	BUY	$1.18 - $6.03 $4,125 - $21,080	3,496 Added 2.12%	168,218 $950,000
Q3 2023 Nov 13, 2023	SELL	$1.81 - $3.89 $17,442 - $37,487	-9,637 Reduced 5.53%	164,722 $306,000
Q2 2023 Aug 10, 2023	BUY	$2.75 - $3.77 $166,281 - $227,956	60,466 Added 53.09%	174,359 $479,000
Q1 2023 May 09, 2023	BUY	$3.1 - $9.02 $308,251 - $896,912	99,436 Added 687.81%	113,893 $357,000
Q4 2022 Feb 10, 2023	BUY	$5.42 - $10.24 $78,356 - $148,039	14,457 New	14,457 $85,000

Others Institutions Holding CCCC

# of Institutions

119

Shares Held

53.8M

Call Options Held

331K

Put Options Held

145K

Ra Capital Management, L.P. Boston, MA

4.88M
Shares

$27.8 Million
0.34% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

4.85M
Shares

$27.6 Million
0.12% of portfolio
Black Rock Inc. New York, NY

4.55M
Shares

$25.9 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

4.05M
Shares

$23.1 Million
1.9% of portfolio
Vanguard Group Inc Valley Forge, PA

3.56M
Shares

$20.3 Million
0.0% of portfolio

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $279M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account